CancerVax Corporation

Biotech company reports fourth quarter net loss of $14.3M

Published in Oncology Business Week, April 3rd, 2005

CancerVax Corporation (CNVX), a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer, announced its unaudited financial results for the fourth quarter and year ended December 31, 2004.

For the fourth quarter ended December 31, 2004, CancerVax reported a net loss of $14.3 million, as compared to a net loss of $11.1 million for the same period in 2003. For the year ended December 31, 2004, CancerVax reported a net loss of $55.6 million, as compared to a net loss of $37.6 million for the same period in 2003.

In December 2004, CancerVax announced the signing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2005-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry